HeartBeam Inc. (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, included participation from key stakeholders such as ClearCardio(TM), company leadership, and institutional investors. The funds are earmarked to accelerate the commercialization of HeartBeam’s FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of artificial intelligence capabilities, and general corporate purposes.
This capital infusion is a critical step for HeartBeam as it scales up efforts to bring its innovative cardiac monitoring technology to market. The company’s platform is designed to be the first cable-free device capable of collecting ECG signals in three dimensions, from three non-coplanar directions, and synthesizing them into a standard 12-lead ECG. This technology aims to enable physicians to identify cardiac health trends and acute conditions remotely, directing patients to appropriate care outside of traditional medical facilities.
HeartBeam’s progress is underscored by recent FDA clearances. In December 2024, the company received FDA clearance for arrhythmia assessment, and in December 2025, its 12-lead ECG synthesis software also gained clearance. The company holds over 20 issued patents related to its technology enablement, positioning it strongly in the cardiac monitoring space.
The successful closing of this offering reflects investor confidence in HeartBeam’s potential to redefine cardiac health management. With the new funds, the company intends to advance its extended-wear patch technology, which could provide continuous monitoring for patients at risk of heart attacks. Additionally, the investment in AI capabilities is expected to enhance the diagnostic accuracy and predictive power of HeartBeam’s platform.
For more details on the offering, refer to the full press release at https://ibn.fm/9iNYY. Information about HeartBeam’s cleared indications for use is available at https://www.heartbeam.com/indications.
